Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Novartis Pharmaceuticals
CONTACT
Novartis Pharmaceuticals
CONTACT
Lead
Novartis Pharmaceuticals
This is a two-part, FIH, Phase 1, open-label, uncontrolled, ascending dose study designed to evaluate the safety and tolerability of DKB903, in participants with RA and participants with SLE.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted